Does parp inhibitor therapy treat pancreatic cancer?

PARP inhibitors interfere with a DNA-repair process. Some pancreatic tumours have inherited or tumour-acquired changes in another repair pathway, including BRCA-related changes, which can make this approach relevant. Tumour profiling and, when appropriate, inherited genetic testing help the oncology team understand whether the biology fits this treatment.

The medicine may be considered after earlier treatment has controlled the cancer, or in another setting selected by the specialist. The decision also takes account of previous medicines, blood counts, kidney and liver function, symptoms and the goals of care. A genetic result may have implications for relatives, so ask about counselling.

Ask whether your tumour has been tested for DNA-repair changes and whether inherited testing is appropriate. Give the team a complete list of medicines and supplements. Blood tests may be needed before and during treatment. Take the medicine exactly as prescribed, keep a record of symptoms, and tell the team about side effects before making changes.

Contact your oncology team urgently for fever, chills, unusual bleeding or bruising, severe breathlessness, chest pain, fainting or profound weakness. Nausea, tiredness and bowel changes can occur, while changes in blood counts may require prompt review and supportive treatment.

Ask whether the expected benefit is based on a tumour or inherited DNA-repair finding, what treatment goal applies, how monitoring will work, and what alternatives are available. Ask how results could affect close relatives and where to obtain genetic counselling.